Axial Spondyloarthritis Drug Market 2022-2028

Description

List of Tables

Global Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)

The global axial spondyloarthritis drug market is anticipated to grow at a substantial CAGR of 4.1% during the forecast period. During the forecast period, the global axial spondyloarthritis drug market is expected to be driven by an increase in the number of approved biosimilars and an increase in the prevalence of axial spondyloarthritis. Furthermore, the increase in research and development activities, and the high unmet need for existing treatment, will benefit the axial spondyloarthritis drug market in the forecast year. The high cost of biologics, on the other hand, is expected to limit the global axial spondyloarthritis drug market.

The global axial spondyloarthritis drug market is segmented based on type and distribution channel. Based on the type, the market is sub-segmented into the certolizumab pegol, etanercept biosimilar, ixekizumab, and others. Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Etanercept Biosimilar is anticipated to have a significant market share in the market. Etanercept Biosimilar is a biological medication that works by suppressing a soluble inflammatory cytokine called tumor necrosis factor (TNF). Etanercept is used to treat rheumatoid, juvenile rheumatoid, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, among other conditions.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds a significant share in the market after the Asia Pacific. The region's dominance is due to a higher percentage of total income spent on health care compared to other economies, adequate reimbursement, along with widespread awareness.

The major companies serving the global axial spondyloarthritis drug market include AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Novartis AG, Panacea Biotec Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2020, Novartis AG announced that Secukinumab, an IL-17a inhibitor, had been approved by the US Food and Drug Administration for the treatment of psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

Research Methodology

The market study of the global axial spondyloarthritis drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Axial Spondyloarthritis Drug Market Research and Analysis by Type

2. Global Axial Spondyloarthritis Drug Market Research and Analysis by Distribution Channel

The Report Covers:

Comprehensive Research Methodology of the global axial spondyloarthritis drug market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global axial spondyloarthritis drug market.
Insights about market determinants that are stimulating the global axial spondyloarthritis drug market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026366

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Axial spondyloarthritis drug Market
Recovery Scenario of Global Axial spondyloarthritis drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. AstraZeneca Plc.
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Eli Lilly and Co.
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Johnson & Johnson Services, Inc.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. Novartis AG
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Panacea Biotec Ltd.
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Axial Spondyloarthritis Drug Market by Type
- 4.1.1. Certolizumab Pegol
- 4.1.2. Etanercept Biosimilar
- 4.1.3. Ixekizumab
- 4.1.4. Others (Secukinumab)

4.3.Global Axial Spondyloarthritis Drug Market by Distribution Channel

4.3.1. Hospital Pharmacies

4.3.2 Retail Pharmacies

4.3.3 Online Pharmacies

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abbott
6.2. AbbVie Inc.
6.3. Amgen Inc.
6.4. GlaxoSmithKLine Plc.
6.5. Kyowa Kirin Co., Ltd.
6.6. Merck & Co. Inc.
6.7. Pfizer Inc.
6.8. Sandoz International GmbH
6.9. KYOCERA Corp.
6.10. Sun Pharmaceutical Industries Ltd.
6.11. UCB S.A.